Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Deep vein thrombosis? 259 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 259 reports of Deep vein thrombosis have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.3% of all adverse event reports for PEMBROLIZUMAB.

259
Reports of Deep vein thrombosis with PEMBROLIZUMAB
0.3%
of all PEMBROLIZUMAB reports
61
Deaths
146
Hospitalizations

How Dangerous Is Deep vein thrombosis From PEMBROLIZUMAB?

Of the 259 reports, 61 (23.6%) resulted in death, 146 (56.4%) required hospitalization, and 23 (8.9%) were considered life-threatening.

Is Deep vein thrombosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 259 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Deep vein thrombosis?

LENALIDOMIDE (3,286) RIVAROXABAN (3,180) TESTOSTERONE (2,213) APIXABAN (1,944) ETHINYL ESTRADIOL\ETONOGESTREL (1,577) RITUXIMAB (1,287) METHOTREXATE (1,146) DROSPIRENONE\ETHINYL ESTRADIOL (1,139) DEXAMETHASONE (1,067) ADALIMUMAB (1,056)

Which PEMBROLIZUMAB Alternatives Have Lower Deep vein thrombosis Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Deep vein thrombosis Reports All Drugs Causing Deep vein thrombosis PEMBROLIZUMAB Demographics